Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND The efficacy of antidiabetic agents for the treatment of non-alcoholic fatty liver disease (NAFLD) remains unclear. AIM To conduct a meta-analysis to study the efficacy of pioglitazone and three novel anti-diabetic agents: glucagon-like peptide-1 (GLP-1) agonists, sodium-glucose co-transporter-2 (SGLT2) inhibitors, and dipeptidyl-peptidase-4 (DPP4) inhibitors in treating NAFLD. METHODS Online databases were searched in May 2020 for randomized clinical trials. Results from random-effects meta-analysis are presented as weighted mean differences (WMDs) or standard mean differences (SMDs) and corresponding 95% confidence intervals (CIs). RESULTS Twenty-six studies (n=946 NAFLD patients) were included. Reductions in ALT were seen with all four drugs: pioglitazone (MD -38.41, p<0.001), SGLT2 inhibitors (MD -16.17, p<0.001), GLP-1 agonists (MD -27.98, p=0.04) and DPP-4 inhibitors (MD -7.41, p<0.001). Pioglitazone (SMD -1.01; p<0.001) and GLP-1 agonists (SMD -2.53, p=0.03) also demonstrated significant improvements in liver steatosis. SGLT2 inhibitors (SMD -4.64, p=0.06) and DPP-4 (SMD -2.49, p=0.06) inhibitors trended towards reduced steatosis; however, these results were non-significant. CONCLUSION Pioglitazone demonstrates significant improvements in transaminases and liver histology in both diabetic and non-diabetic NAFLD patients. Early evidence from diabetic NAFLD patients suggests that novel antidiabetics may lead to improvements in liver enzymes and hepatic steatosis, and this should encourage further research into possible utility of these drugs in treating NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9607 · Cited by 449
Boettcher, E., Csako, G., Pucino, F., Wesley, R., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04912.x · Cited by 318
Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.12.007 · Cited by 138
Research works printed but not linked: 13
- Ballestri, 2016, Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis, J Gastroenterol Hepatol, 31, 936, 10.1111/jgh.13264 · DOI · Paper page
- Mantovani, 2018, Nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: a meta-analysis, Diabetes Care, 41, 372, 10.2337/dc17-1902 · DOI · Paper page
- Sattar, 2018, Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial, Diabetologia, 61, 2155, 10.1007/s00125-018-4702-3 · DOI · Paper page
- Ito, 2017, Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial, Diabetes Care, 40, 1364, 10.2337/dc17-0518 · DOI · Paper page
- Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Razavizade, 2013, The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial, Hepat Mon, 13, e9270, 10.5812/hepatmon.9270 · DOI
- Lutchman, 2007, The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis, Hepatology, 46, 424, 10.1002/hep.21661 · DOI · Paper page
- Shibuya, 2018, Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: a prospective randomized controlled pilot study, Diabetes Obes Metab, 20, 438, 10.1111/dom.13061 · DOI · Paper page
- Cui, 2016, Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial, J Hepatol, 65, 369, 10.1016/j.jhep.2016.04.021 · DOI · Paper page
- Deng, 2017, Short article: a randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease, Eur J Gastroenterol Hepatol, 29, 297, 10.1097/MEG.0000000000000780 · DOI · Paper page
- Macauley, 2015, Effect of vildagliptin on hepatic steatosis, The J Clin Endocrinol Metab, 100, 1578, 10.1210/jc.2014-3794 · DOI · Paper page
- Alghaith, 2019, PDG2 efficacy of pioglitazone in improving liver histology scores of patients with non-alcoholic fatty liver disease: a systematic-review and meta-analysis, Value Health, 22, S163, 10.1016/j.jval.2019.04.681 · doi:10.1016/j.jval.2019.04.681
- Prat, 2018, The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD), Hormones, 17, 219, 10.1007/s42000-018-0021-9 · DOI
Cited by
Shao, S.-C., Kuo, L.-T., Chien, R.-N., Hung, M.-J., & Lai, E. C.-C. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001956 · Cited by 43
Gu, Y., Sun, L., He, Y., Yang, L., Deng, C., Zhou, R., Kong, T., Zhang, W., Chen, Y., Li, J., et al. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2172397 · Cited by 36
Ivancovsky Wajcman, D., Byrne, C. J., Dillon, J. F., Brennan, P. N., Villota-Rivas, M., Younossi, Z. M., Allen, A. M., Crespo, J., Gerber, L. H., & Lazarus, J. V. (2026) · Hepatology · doi:10.1097/hep.0000000000001058 · Cited by 33
Anti-inflammatory effects of GLP-1 in patients with COVID-19
Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1964955 · Cited by 21
Metadata
- Authors
- Kumar, J., Memon, R. S., Shahid, I., Rizwan, T., Zaman, M., Menezes, R. G., Kumar, S., Siddiqi, T. J., & Usman, M. S.
- Venue
- Digestive and Liver Disease
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 53
- Issue
- 1
- Pages
- 44-51
- ISSN
- 1590-8658 (ISSN-L)
- OpenAlex
- W3083948332
- Cited by
- 68
- References
- 8
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. https://app.cochat.ai/papers/10.1016/j.dld.2020.08.021
- The paper
- Kumar, J., Memon, R. S., Shahid, I., Rizwan, T., Zaman, M., Menezes, R. G., Kumar, S., Siddiqi, T. J., & Usman, M. S. (2021). Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2020.08.021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.